(Q38472433)

3 September 2017

title

Epigenetic drugs for cancer treatment and prevention: mechanisms of action (English)

1 reference

3 September 2017

Xiao-Dan Yu

1

1 reference

3 September 2017

Z Sheng Guo

series ordinal

2

1 reference

3 September 2017

publication date

1 October 2010

1 reference

3 September 2017

published in

Biomolecular concepts

1 reference

3 September 2017

volume

1

1 reference

3 September 2017

issue

3-4

1 reference

3 September 2017

page(s)

239-251

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

3 September 2017

copyright license

start time

1 October 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetics and cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Induction of Tumors in Mice by Genomic Hypomethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Molecular pathology shows p16 methylation in nonadenomatous pituitaries from patients with Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The epigenetic progenitor origin of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Replication timing and epigenetic reprogramming of gene expression: a two-way relationship?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Replication timing as an epigenetic mark

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

H2A.Z-mediated localization of genes at the nuclear periphery confers epigenetic memory of previous transcriptional state

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Regulation and epigenetic control of transcription at the nuclear periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The complex language of chromatin regulation during transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Chromatin modifications and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

An essential role for DNA methyltransferase 3a in melanoma tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

CpG island methylator phenotype in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

CpG island methylator phenotype (CIMP) in cancer: causes and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Transient cyclical methylation of promoter DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Cyclical DNA methylation of a transcriptionally active promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The colorful history of active DNA demethylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Combinatorial patterns of histone acetylations and methylations in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone lysine demethylases: emerging roles in development, physiology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

High-resolution profiling of histone methylations in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Regulation of histone methylation by demethylimination and demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

DNA methylation and histone modifications: teaming up to silence genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Linking DNA methylation and histone modification: patterns and paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The multi-domain protein Np95 connects DNA methylation and histone modification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Valproate induces replication-independent active DNA demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic opportunities and challenges in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Decitabine: a historical review of the development of an epigenetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Targeting of 5-aza-2'-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

5-Aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45- and p53-dependent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

DNA damage triggers p21WAF1-dependent Emi1 down-regulation that maintains G2 arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

HDAC expression and clinical prognosis in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Acetylation of Stat1 modulates NF-kappaB activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

21 January 2018

Heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Acetylation of non-histone proteins modulates cellular signalling at multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Targeting tumor angiogenesis with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Identification of cell-active lysine specific demethylase 1-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Sp1-mediated TRAIL induction in chemosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic control of the immune escape mechanisms in malignant carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Intelligent design: combination therapy with oncolytic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The rationale and potential of cancer chemoprevention with special emphasis on breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Molecular targets for cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Cancer prevention: epigenetics steps up to the plate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetics in Carcinogenesis and Cancer Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Introduction: diet, epigenetic events and cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Molecular basis for cancer chemoprevention by green tea polyphenol EGCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

(-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

(-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Protein phosphatase-2A is a target of epigallocatechin-3-gallate and modulates p53-Bak apoptotic pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigallocatechin gallate dose-dependently induces apoptosis or necrosis in human MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Autophagy suppresses tumorigenesis through elimination of p62

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Nrf2 activation by sulforaphane restores the age-related decrease of T(H)1 immunity: role of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FBMC.2010.020

21 January 2018

Identifiers

DOI

10.1515/BMC.2010.020

1 reference

release_nvi7mrl3t5grveinoapwgko5uy

3 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nvi7mrl3t5grveinoapwgko5uy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference